1.65
0.46 (38.66%)
| Previous Close | 1.19 |
| Open | 1.21 |
| Volume | 4,787,132 |
| Avg. Volume (3M) | 412,581 |
| Market Cap | 54,621,436 |
| Price / Book | 17.82 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.110 |
| Total Debt/Equity (MRQ) | 6.71% |
| Current Ratio (MRQ) | 1.91 |
| Operating Cash Flow (TTM) | -4.91 M |
| Levered Free Cash Flow (TTM) | -3.52 M |
| Return on Assets (TTM) | -99.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Jupiter Neurosciences, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 54.18% |
| % Held by Institutions | 1.17% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jul 2025 | Announcement | From Fighting Inflammation To Regenerating Cells: How Jupiter Neurosciences Is Putting The Pep Back In Our Step As We Age |
| 30 Jun 2025 | Announcement | Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery |
| 27 Jun 2025 | Announcement | Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science |
| 23 Jun 2025 | Announcement | Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador |
| 16 Jun 2025 | Announcement | How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success |
| 09 Jun 2025 | Announcement | Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |